Your session is about to expire
← Back to Search
CPX-351 for Acute Myeloid Leukemia (CPX GO Trial)
CPX GO Trial Summary
This trial is testing a new combination therapy of CPX-351 and gemtuzumab ozogamicin (GO) to treat acute myeloid leukemia (AML) in patients who are ineligible for standard intensive induction chemotherapy. The goal is to establish the safety and feasibility of the combination and to assess its efficacy and impact on patients' quality of life.
- Acute Myeloid Leukemia
CPX GO Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CPX GO Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are researchers currently recruiting individuals for this experiment?
"This research trial is actively recruiting, as indicated on clinicaltrials.gov; with its posting taking place on August 23rd 2019 and the most recent update occurring on December 21st 2021."
What is the aggregate patient count for this trial?
"Affirmative. The online listing on clinicaltrials.gov denotes that this experiment is actively looking for participants, which was initially posted on August 23rd 2019 and recently edited in December 2021. This study requires a total of 30 volunteers from one site."
Has CPX-351 obtained regulatory authorization from the FDA?
"Our team at Power rated the safety of CPX-351 as 1 due to it being a Phase 1 trial, which indicates limited knowledge regarding its efficacy and safety."
What precedent has been established with regards to CPX-351 trials?
"At present, 273 studies are actively being run for CPX-351, 66 of which have reached the third phase. Notably, 12644 medical centres across New york host trials for this drug."
Share this study with friends
Copy Link
Messenger